静脉血栓治疗用药拜瑞妥效果如何？

(Rivaroxaban) has good efficacy mainly because Xarelto is a highly selective oral drug that directly inhibits factor Xa. By inhibiting factor Xarelto does not inhibit thrombin (activated factor II) and has no proven effect on platelets. Xarelto was jointly developed by Bayer and Johnson & Johnson and is used clinically for the prevention and treatment of deep vein thrombosis. Today we will learn more about the effectiveness of Xarelto, a drug used to treat venous thrombosis.

Objective To observe the clinical effect of Xarelto (rivaroxaban) tablets in the treatment of venous thrombosis.

Methods A total of 150 patients diagnosed with venous thrombosis who were admitted recently (from December 2016 to December 2018) were randomly divided into a control group (75 cases) and an experimental group (75 cases). The control group was treated with conventional low-molecular-weight heparin calcium, and the patients in the experimental group were treated with conventional low-molecular-weight heparin calcium. Xarelto (rivaroxaban) tablets were used for treatment. The two groups of patients were compared before and after treatment, and the coagulation function indicators, safety and venous thrombosis incidence rate after treatment were compared. As a result, before treatment, there was no statistically significant difference in the coagulation function indicators between the two groups of patients (P>0.05), which was comparable.

After treatment, various coagulation indicators of patients in the experimental group were significantly better than those in the control group, and the difference was statistically significant (P<0.001). The safety rate of patients in the experimental group was 97.33%, and the incidence rate of DVT was 1.33%. The safety rate of patients in the control group was 82.67%, and the incidence rate of DVT was 9.33%. The difference was statistically significant (P<0.05).

Conclusion: Xarelto tablets can significantly improve the coagulation function of patients after surgery, reduce bleeding from surgical incisions, and reduce the incidence of subcutaneous ecchymosis and petechiae. The medication is safe and can effectively prevent the occurrence of venous thrombosis. The effect is ideal.

A foreign study shows that intravenous thrombolysis is recommended when the plasma concentration of ng/ml, pure endovascular therapy was performed.

  In this study, measurements of plasma levels of Xarelto (rivaroxaban) enabled treatment of nearly one-third of patients who were originally considered ineligible for emergency intravenous thrombolysis. In addition, no bleeding events occurred in any of the 114 patients taking Xarelto in this study.

The above is the content of the effect of (Rivaroxaban), I hope it can help you!

Recommended related hot articles: /newsDetail/76637.html